Top news of the week: 29.08.2022.
Health care
Supreme court
Balance sheet
DNA replication
Organism
Bristol-Myers Squibb
Smart stuff from my colleague, Leah Nebbia, on outcomes-based agreements.
“At the end of the day, these are risk-sharing agreements, and the data suggests that the benefit is worth the risk.”
https://t.co/dZvR4jF1ZW
Open
With two new expensive gene therapy approvals, outcomes-based pricing deals grab the spotlight again
Two recent approvals for two expensive gene therapies for blood disorders — BioMarin's $1.5 million Roctavian in the EU for hemophilia A and bluebird bio's $2.8 million Zynteglo in the US ...
@UCSF @GladstoneInst @igisci @HIPI_Inserm @OhioStateMAE @GenScript @UCSFCancer @UCBerkeley @czbiohub @MarsonLab A cellular engineering breakthrough: High-yield CRISPR without viral vectors #NBTintheNews via @GladstoneInst https://t.co/1hmPscaufR
Open
A Cellular Engineering Breakthrough: High-Yield CRISPR Without Viral Vectors
Scientists develop a new approach that produces enough cells for therapeutic applications
RT @chrissyfarr: 🚨New Second Opinion🚨
My list of 25 active pre-seed and seed investors in digital health.
* I wrote this for founders
* And for my own sanity, so I've got a cheatsheet to refer startups to awesome funds
* Plz submit your fund for the next update!
https://t.co/5Yh0ZFWk83
Open
Who are the most active early-stage investors in digital health?
We compiled a short-list of 25 so you don't have to
Management's ongoing execution is raising the biopharma's profile among investors, noted an Oppenheimer report.
First Data Due by Year End 2022 From Study of New HAE Drug: https://t.co/r80wvkLFc9
$ATXS #biopharma #HAE @AstriaTx
Open
First Data Due by Year End 2022 From Study of New HAE Drug Research Report
Management's ongoing execution is raising the biopharma's profile among investors, noted an Oppenheimer report.